$QGEN
Qiagen N.V.
NYSE · Healthcare · Biological Products, (No Diagnostic Substances) · Pl Venlo
QGEN chart
What traders are saying about $QGEN
Latest postsQiagen N.V. news
- Global Genome Annotation Services Market Report 2026: Trends and Forecast to 2030 | Capitalize on AI and Precision Medicine with Roche, Thermo Fisher, Illumina, QIAGEN
Yahoo Finance ·
- Large Language Model (LLM)-Powered Genomic Report Drafting Global Market Report 2026 | Capitalize on 23.6% CAGR Through 2030 with Illumina, QIAGEN, Tempus AI and SOPHiA GENETICS
Yahoo Finance ·
- Genomic Variant Prioritization Artificial Intelligence (AI) Global Market Report 2026 | Capitalize on 26.5% CAGR with Illumina, QIAGEN, Thermo Fisher Scientific and Tempus AI
Yahoo Finance ·
- Global Ribonucleic Acid (RNA) Extraction Kits Market Report 2026 | Capitalize on 10.1% CAGR to $3.68B by 2030 as Roche, Thermo Fisher, QIAGEN and Merck Accelerate Automation
Yahoo Finance ·
- Deoxyribonucleic Acid (DNA) Profiling Kits Market Report 2026-2030 | Capitalize on 12.2% CAGR as Thermo Fisher Scientific, Illumina, QIAGEN and Promega Drive NGS, AI and Automation
Yahoo Finance ·
- Weekly Recap: 2026 guidance suspended and Q3 revenue beats outlook
TradingView ·
- Qiagen N.V. (1QGEN.MI) Seasonal Returns Chart
Yahoo! Finance Canada ·
- About Qiagen NV (Stove Tokenized Stock)
Coinbase ·
- QIAGEN N.V. (QIA) JPMorgan Reports 5.05% Holding
TradingView ·
- QIAGEN N.V. (QIA) Reports JPMorgan Voting Rights Notification
TradingView ·
- Release according to Article 40, Section 1 of the WpHG
TradingView ·
- QIAGEN N.V. (QIA) Reports BlackRock Holds 12.97% of Voting Rights
TradingView ·
Qiagen N.V. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $2.09B | $1.98B | $1.97B | $2.14B |
| Net income | $424.9M | $83.6M | $341.3M | $423.2M |
| Diluted EPS | $1.94 | $0.37 | $1.48 | $1.84 |
| Total assets (year end) | $6.28B | $5.69B | $6.12B | $6.29B |
| Cash and equivalents (year end) | $839.0M | $663.6M | $668.1M | $730.7M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Qiagen N.V.
- Ticker
- QGEN (NYSE)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Pl Venlo
- Incorporated in
- Netherlands
- Fiscal year end
- December 31
- SEC CIK
- 1015820
- Former names
- QIAGEN NV
Frequently asked questions
What exchange is Qiagen N.V. listed on?
Qiagen N.V. trades on the NYSE under the ticker symbol QGEN.
What industry is Qiagen N.V. in?
Qiagen N.V. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Qiagen N.V. headquartered?
Qiagen N.V.'s business address on file with the SEC is in Pl Venlo.
When does Qiagen N.V.'s fiscal year end?
Qiagen N.V.'s fiscal year ends on December 31.
How much revenue did Qiagen N.V. report?
Qiagen N.V. reported $2.09B in revenue for calendar year 2025, according to its SEC filings.